Elliot Offman1, Michael Davidson2,3, Mohammad Abu-Rashid4,5, Peng Chai5, Catarina Nilsson6. 1. Clinical Pharmacology and Pharmacometrics, Celerion, 100 Boulevard Alexis-Nihon, Bureau (Suite) 360, Montreal, QC, H4M 2N8, Canada. Elliot.offman@celerion.com. 2. Department of Cardiology, University of Chicago Pritzker School of Medicine, Chicago, IL, USA. 3. Corvidia Therapeutics, Waltham, MA, USA. 4. Clinical Pharmacology and Pharmacometrics, Celerion, 100 Boulevard Alexis-Nihon, Bureau (Suite) 360, Montreal, QC, H4M 2N8, Canada. 5. Data Management and Biometrics, Celerion, Montreal, QC, Canada. 6. Quantitive Clinical Pharmacology, AstraZeneca Gothenburg, Mölndal, Sweden.
Abstract
BACKGROUND: Omega-3 carboxylic acids (OM3-CA) contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in free fatty acid form. Per gram, OM3-CA includes approximately half as much EPA as icosapent ethyl (IPE), an ethyl ester formulation of EPA. OBJECTIVE: The study aim was to assess systemic EPA and EPA + DHA exposures and plasma lipid parameters following multiple OM3-CA or IPE doses under low-fat dietary conditions, and dose proportionality after OM3-CA administration. METHODS: In this phase 1, two-cohort, open-label study (N = 114), participants following the Therapeutic Lifestyle Changes diet received either OM3-CA 2 g once daily for 10 days then OM3-CA 4 g once daily for 10 days, or IPE 2 g twice daily for 20 days. Exposure was considered similar if the 90% confidence intervals (CIs) of geometric least-squares mean (LSM) ratios for key pharmacokinetic parameters were within 80-125%. RESULTS: Baseline-adjusted steady-state EPA exposure was similar after dosing with OM3-CA 4 g/day versus IPE 4 g/day (LSM ratio, area under the concentration-time curve from time 0 to 24 h: 93.9%; 90% CI 85.6, 103.0). Combined molar-equivalent EPA + DHA exposure was 30.6% higher following OM3-CA 4 g/day than IPE 4 g/day. EPA and DHA exposure increased approximately proportionally with OM3-CA dose (2-4 g/day). Changes from baseline in lipid parameters were similar in the two cohorts. CONCLUSION: EPA exposure from OM3-CA and IPE was similar under low-fat dietary conditions, despite OM3-CA containing only approximately half as much EPA as IPE. EPA and DHA exposure from OM3-CA increased proportionally with dose.
BACKGROUND:Omega-3 carboxylic acids (OM3-CA) contains eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in free fatty acid form. Per gram, OM3-CA includes approximately half as much EPA as icosapent ethyl (IPE), an ethyl ester formulation of EPA. OBJECTIVE: The study aim was to assess systemic EPA and EPA + DHA exposures and plasma lipid parameters following multiple OM3-CA or IPE doses under low-fat dietary conditions, and dose proportionality after OM3-CA administration. METHODS: In this phase 1, two-cohort, open-label study (N = 114), participants following the Therapeutic Lifestyle Changes diet received either OM3-CA 2 g once daily for 10 days then OM3-CA 4 g once daily for 10 days, or IPE 2 g twice daily for 20 days. Exposure was considered similar if the 90% confidence intervals (CIs) of geometric least-squares mean (LSM) ratios for key pharmacokinetic parameters were within 80-125%. RESULTS: Baseline-adjusted steady-state EPA exposure was similar after dosing with OM3-CA 4 g/day versus IPE 4 g/day (LSM ratio, area under the concentration-time curve from time 0 to 24 h: 93.9%; 90% CI 85.6, 103.0). Combined molar-equivalent EPA + DHA exposure was 30.6% higher following OM3-CA 4 g/day than IPE 4 g/day. EPA and DHA exposure increased approximately proportionally with OM3-CA dose (2-4 g/day). Changes from baseline in lipid parameters were similar in the two cohorts. CONCLUSION:EPA exposure from OM3-CA and IPE was similar under low-fat dietary conditions, despite OM3-CA containing only approximately half as much EPA as IPE. EPA and DHA exposure from OM3-CA increased proportionally with dose.
Authors: Lisa J Schwellenbach; Kari L Olson; Karen J McConnell; Ryan S Stolcpart; James D Nash; John A Merenich Journal: J Am Coll Nutr Date: 2006-12 Impact factor: 3.169
Authors: John J P Kastelein; Kevin C Maki; Andrey Susekov; Marat Ezhov; Borge G Nordestgaard; Ben N Machielse; Douglas Kling; Michael H Davidson Journal: J Clin Lipidol Date: 2013-10-14 Impact factor: 4.766
Authors: Michael H Davidson; Judith Johnson; Michael W Rooney; Michael L Kyle; Douglas F Kling Journal: J Clin Lipidol Date: 2012-01-24 Impact factor: 4.766
Authors: Kevin C Maki; Harold E Bays; Christie M Ballantyne; James A Underberg; John J P Kastelein; Judith B Johnson; James J Ferguson Journal: J Am Heart Assoc Date: 2022-03-01 Impact factor: 6.106
Authors: Gael Nana; Suparna Mitra; Henry Watson; Caroline Young; Henry M Wood; Sarah L Perry; Amanda D Race; Philip Quirke; Giles J Toogood; Paul M Loadman; Mark A Hull Journal: J Nutr Date: 2021-08-07 Impact factor: 4.798